Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for CAR-T and TCR Complex Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD247 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD247 Intracellular Domain (ICD) Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for in vitro phosphorylation assays. |
View CD247 Products |
| Gene Delivery | CD247 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and TCR reconstitution. |
View CD247 Products |
| Benchmark Ab | Anti-CD247 Recombinant Antibody Sequence-verified positive control for Western Blot, Flow Cytometry, and IP. |
View CD247 Products |
| Validator | CD247 siRNA Set For knockdown verification in primary T-cells and Jurkat models. |
View CD247 Products |
| Related Target A | CD3E (CD3 Epsilon) Essential partner subunit in the TCR-CD3 complex; critical for T-cell activation signaling. |
View CD3E Products |
| Related Target B | LCK (LCK Proto-Oncogene) Src family tyrosine kinase responsible for phosphorylating the ITAMs of CD247. |
View LCK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting intracellular ITAM phosphorylation assays | High-purity CD247 ICD recombinant proteins with verified sequence and theoretical MW confirmation. |
| Multi-subunit TCR complex assembly study | Lentiviral vectors for stable, stoichiometric co-expression of CD3 components (Epsilon, Delta, Gamma, Zeta). |
| Lack of reliable positive controls | Sequence-verified monoclonal antibodies targeting specific CD247 intracellular epitopes. |
| Off-target signaling validation | Validated siRNA sets included for target-specific knockdown verification. |
Live CD247 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD247 therapeutics is intensifying, with major players shifting focus from traditional mAbs to cell therapy and engineered TCR signaling domains. As first-generation CAR-T therapies reach mature clinical stages, the next wave of R&D is targeting the optimization of the CD247 (CD3zeta) signaling domain to overcome T-cell exhaustion and enhance persistence in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T Cell Therapy | Novartis, Kite/Gilead, Bristol Myers Squibb | Hematological Malignancies, Solid Tumors | CD247 signaling domain optimization & ITAM phosphorylation assays (Need high-purity ICD proteins) |
| TCR-T Therapy | Adaptimmune, GSK | Synovial Sarcoma, Solid Tumors | TCR-CD3 complex assembly & stability verification (Need Lentivirus for stable cell lines) |
| Gene Correction / Therapy | Academic Institutions, Biotech Startups | CD3zeta Deficiency, Autoimmune Diseases | Expression rescue and reconstitution assays (Need sequence-verified CD247 Promise-ORF) |